JP2021527053A5 - - Google Patents
Info
- Publication number
- JP2021527053A5 JP2021527053A5 JP2020567857A JP2020567857A JP2021527053A5 JP 2021527053 A5 JP2021527053 A5 JP 2021527053A5 JP 2020567857 A JP2020567857 A JP 2020567857A JP 2020567857 A JP2020567857 A JP 2020567857A JP 2021527053 A5 JP2021527053 A5 JP 2021527053A5
- Authority
- JP
- Japan
- Prior art keywords
- amino
- pharmaceutically acceptable
- carboxylic acid
- acceptable salt
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862681913P | 2018-06-07 | 2018-06-07 | |
| US62/681,913 | 2018-06-07 | ||
| PCT/US2019/035934 WO2019236938A1 (en) | 2018-06-07 | 2019-06-07 | Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and vigabatrin in the treatment of developmental disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021527053A JP2021527053A (ja) | 2021-10-11 |
| JP2021527053A5 true JP2021527053A5 (https=) | 2022-06-14 |
| JP7387179B2 JP7387179B2 (ja) | 2023-11-28 |
Family
ID=68765508
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020567857A Active JP7387179B2 (ja) | 2018-06-07 | 2019-06-07 | 発達障害の処置における（ｓ）－３－アミノ－４－（ジフルオロメチレニル）シクロペンタ－１－エン－１－カルボン酸および関連化合物、（１ｓ，３ｓ）－３－アミノ－４－（ジフルオロメチリデン）シクロペンタン－１－カルボン酸ならびにビガバトリンの使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US10813899B2 (https=) |
| EP (1) | EP3813816B1 (https=) |
| JP (1) | JP7387179B2 (https=) |
| KR (1) | KR102744830B1 (https=) |
| CN (1) | CN112770739B (https=) |
| AU (1) | AU2019280980B2 (https=) |
| CA (1) | CA3102786A1 (https=) |
| ES (1) | ES2948263T3 (https=) |
| IL (2) | IL279220B2 (https=) |
| MX (2) | MX2020013290A (https=) |
| PL (1) | PL3813816T3 (https=) |
| WO (1) | WO2019236938A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3102786A1 (en) | 2018-06-07 | 2019-12-12 | Ovid Therapeutics Inc. | Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and vigab atrin in the treatment of developmental disorders |
| US11738020B2 (en) | 2018-08-18 | 2023-08-29 | Ftf Pharma Private Limited | Stable liquid vigabatrin pharmaceutical composition for oral dosage |
| WO2024058812A1 (en) | 2022-09-16 | 2024-03-21 | Pyros Pharmaceuticals, Inc. | Vigabatrin liquid pharmaceutical composition |
| US20240285565A1 (en) * | 2023-02-17 | 2024-08-29 | Ovid Therapeutics Inc. | Use of (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of diabetes and pre-diabetes |
| EP4648757A4 (en) * | 2023-02-17 | 2026-01-07 | Ovid Therapeutics Inc | USE OF (S)-3-AMINO-4-(DIFLUOROMETHYLENYL)CYCLOPENT-1-ENE-1-CARBOXYLIC ACID FOR THE TREATMENT OF GASTROINTESTINAL TRACT DISORDERS AND AS AN IMMUNOMODULATING AGENT |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6794413B1 (en) | 2002-07-19 | 2004-09-21 | Northwestern University | Compounds and related methods for inhibition of γ-aminobutyric acid aminotransferase |
| WO2005120496A2 (en) | 2004-05-24 | 2005-12-22 | Regents Of The University Of California | TREATING LEARNING DEFICITS WITH INHIBITORS OF HMG CoA REDUCTASE |
| WO2009033818A2 (en) * | 2007-09-11 | 2009-03-19 | Mondobiotech Laboratories Ag | Use of a peptide as a therapeutic agent |
| CA2790820A1 (en) | 2010-02-25 | 2011-09-01 | Northwestern University | Use (1s,3s)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid as a gaba aminotransferse inhibitor |
| US20130230586A1 (en) | 2010-10-02 | 2013-09-05 | Link Research & Grants Corporation | Treatment of Tinnitus and Related Auditory Dysfunctions |
| US20140315992A1 (en) | 2011-07-07 | 2014-10-23 | The Children's Hospital Of Philadelphia | Genetic Alterations Associated with Autism and the Autistic Phenotype and Methods of Use Thereof for the Diagnosis and Treatment of Autism |
| EP2806867A4 (en) | 2012-01-27 | 2015-09-02 | Catalyst Pharmaceutical Partners Inc | METHOD FOR TREATING TOURETTE SYNDROME WITH GABA AMINO TRANSFERASE INACTIVORS |
| TW201605443A (zh) * | 2013-09-09 | 2016-02-16 | 亞克柏拉有限公司 | 治療ｘ染色體脆折症及相關病症的方法 |
| US20150224164A1 (en) | 2013-11-26 | 2015-08-13 | Neuren Pharmaceuticals Limited | Treatment of autism spectrum disorders using glycyl-l-2-methylprolyl-l-glumatic acid |
| ES2882126T3 (es) | 2014-11-07 | 2021-12-01 | Univ Northwestern | Inhibición de ornitina aminotransferasa con análogos de GABA para el tratamiento de carcinoma hepatocelular |
| US20170348232A1 (en) * | 2016-06-07 | 2017-12-07 | Ovid Therapeutics Inc. | Formulations of gaboxadol for treatment of angelman syndrome, fragile x syndrome and fragile x-associated tremor/ataxia syndrome |
| JP6841821B2 (ja) | 2015-10-09 | 2021-03-10 | ノースウェスタン ユニバーシティ | てんかん、嗜癖および肝細胞癌の処置のためのｇａｂａアミノトランスフェラーゼ不活性化剤としての（ｓ）−３−アミノ−４−（ジフルオロメチレニル）シクロペント−１−エン−１−カルボン酸および関連化合物 |
| US10632088B2 (en) | 2016-10-10 | 2020-04-28 | Northwestern University | Inactivators of Toxoplasma gondii ornithine aminotransferase for treating toxoplasmosis and malaria |
| EP4692048A3 (en) * | 2017-02-08 | 2026-04-01 | Ovid Therapeutics Inc. | Methods of treating cdkl5 disorders with the compound ov329 |
| EP3711761A4 (en) * | 2017-11-14 | 2021-11-24 | SK Biopharmaceuticals Co., Ltd. | USE OF A CARBAMATE COMPOUND TO REDUCE OR TREAT DEVELOPMENTAL DISORDERS, INCLUDING FRAGILE X SYNDROME, ANGELMAN'S SYNDROME, OR RETT'S SYNDROME |
| MX2020012691A (es) | 2018-05-25 | 2021-02-15 | Univ Northwestern | Proceso para la sintesis del acido (s)-3-amino-4-(difluorometileni l)ciclopent-1-eno-1-carboxilico. |
| CA3102786A1 (en) | 2018-06-07 | 2019-12-12 | Ovid Therapeutics Inc. | Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and vigab atrin in the treatment of developmental disorders |
-
2019
- 2019-06-07 CA CA3102786A patent/CA3102786A1/en active Pending
- 2019-06-07 IL IL279220A patent/IL279220B2/en unknown
- 2019-06-07 PL PL19815892.5T patent/PL3813816T3/pl unknown
- 2019-06-07 KR KR1020217000541A patent/KR102744830B1/ko active Active
- 2019-06-07 US US16/434,300 patent/US10813899B2/en active Active
- 2019-06-07 AU AU2019280980A patent/AU2019280980B2/en active Active
- 2019-06-07 WO PCT/US2019/035934 patent/WO2019236938A1/en not_active Ceased
- 2019-06-07 MX MX2020013290A patent/MX2020013290A/es unknown
- 2019-06-07 CN CN201980052607.5A patent/CN112770739B/zh active Active
- 2019-06-07 JP JP2020567857A patent/JP7387179B2/ja active Active
- 2019-06-07 ES ES19815892T patent/ES2948263T3/es active Active
- 2019-06-07 IL IL304270A patent/IL304270B2/en unknown
- 2019-06-07 EP EP19815892.5A patent/EP3813816B1/en active Active
-
2020
- 2020-10-16 US US17/072,511 patent/US11660277B2/en active Active
- 2020-12-07 MX MX2023006497A patent/MX2023006497A/es unknown
-
2023
- 2023-04-19 US US18/302,997 patent/US12285397B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021527053A5 (https=) | ||
| CA2470956A1 (en) | 1-alkyl-1-azoniabicyclo[2.2.2]octane carbamate derivatives and their use as muscarinic receptor antagonists | |
| JP2019524834A5 (https=) | ||
| CL2012001056A1 (es) | Compuestos derivados de cromenona sustituidos, inhibidores de enzimas pi 3 quinasa; composicion farmaceutica; y uso en el tratamiento o prevencion de trastornos de proliferacion celular, tales como tumores enfermedades inflamatorias y fibroticas, asma, diabetes insulinodependiente, entre otras. | |
| JP2024517738A5 (https=) | ||
| US20250144060A1 (en) | Compositions and methods for treating biofilms | |
| UA107578C2 (uk) | Комбінована терапія при лікуванні діабету | |
| JP2014511374A5 (https=) | ||
| JP2007520452A5 (https=) | ||
| US20220296553A1 (en) | Compositions for treating fungal and bacterial biofilms and methods of using the same | |
| JP2020534270A5 (https=) | ||
| AR050463A1 (es) | Analagos de lonidamina y su uso en anticoncepcion masculina y en el tratamiento contra el cancer. | |
| IL292770A (en) | Formulations and dosages of polyethylene glycol-modified oricase | |
| WO2023081482A9 (en) | Combination of a bile acid and a phenyl butyrate compound for the treatment of neurodegenerative diseases | |
| JP2012508256A5 (https=) | ||
| CN104955447A (zh) | 用于减轻口干燥症状和用于治疗口溃疡的局部口腔组合物 | |
| JP2013523628A5 (https=) | ||
| BRPI0411702A (pt) | uso de ácido hialurÈnico para preparar composições para o tratamento de aftas da cavidade oral | |
| JP2022028975A5 (https=) | ||
| JP2022503733A5 (https=) | ||
| JP2020536098A5 (https=) | ||
| MX2025012741A (es) | Composiciones farmaceuticas orales | |
| RU2014151156A (ru) | Налмефен для уменьшения потребления алкоголя у конкретных целевых популяций | |
| JP2018531961A5 (https=) | ||
| JP2021503010A5 (https=) |